CompanyPrivateLianyungang, China

Jiangsu Hengrui Pharmaceuticals

ClinicalTrials.gov

10-QNov 10Latest SEC filing

Nov 10Latest story

November 2026

Hengrui and Braveheart report 52-week data on HRS/BHB-1893 in obstructive HCM

Nov 6Clinical readoutBHB-1893 Braveheart Bio, Inc.